Arthritis Care & Research最新文献

{"title":"International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung Disease.","authors":"Kristofer Andréasson, Arissa Young, Swapna Joshi, Jennifer S Labus, Andrea Hsiu Ling Low, Vanessa Smith, Zsuzsanna McMahan, Susanna Proudman, Antonia Valenzuela, Phoebe Hunter, Grace Hyun Kim, Gracijela Bozovic, Jonathan Goldin, Ezinne Aja, Jonathan P Jacobs, Elizabeth R Volkmann","doi":"10.1002/acr.25623","DOIUrl":"https://doi.org/10.1002/acr.25623","url":null,"abstract":"<p><strong>Objectives: </strong>Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (i.e., gut-lung axis). While intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc-associated interstitial lung disease (ILD) in a multi-national cohort. This study aimed to characterize the intestinal microbiota of SSc-ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity.</p><p><strong>Methods: </strong>SSc patients with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. Quantitative image analysis of high-resolution computed tomography scans of the chest was used to measure radiological extent of ILD (QILD). Multivariate sparse partial least squares analyses were employed to identify a species signature of ILD and to determine whether specific species and functional pathways are associated with QILD.</p><p><strong>Results: </strong>Among 285 participants (mean disease duration of 9.8 years), 62.5% had ILD. In a multivariate analysis of all participants, patients with ILD had a unique microbial signature compared to those without ILD characterized by increased abundance of candidate pathobiont species. In a subgroup of SSc-ILD participants (N=103), specific bacterial species and functional pathways were associated with QILD.</p><p><strong>Conclusion: </strong>This multicenter study demonstrates that distinct intestinal bacterial species are linked to the presence and radiological extent of ILD in SSc. These species and/or their metabolic products may influence ILD pathogenesis and represent novel treatment targets.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration.","authors":"Lindsay N Helget, Bryant R England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R O'Dell, Joshua F Baker, Ted R Mikuls","doi":"10.1002/acr.25622","DOIUrl":"https://doi.org/10.1002/acr.25622","url":null,"abstract":"<p><strong>Objective: </strong>Though used frequently to treat flare, risk of chronic opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed chronic opioids over time.</p><p><strong>Methods: </strong>In this matched cohort study using national Veterans Health Administration (VA) data, multivariable Cox regression was used to examine the association of gout with chronic opioid receipt (defined using a validated administrative algorithm). Gout cases were identified using diagnostic codes and matched with up to 10 non-gout controls by age, sex, and VA enrollment year. In analyses limited to gout, factors associated with chronic opioid exposure were identified.</p><p><strong>Results: </strong>Over a mean follow-up of 4.52 years, gout patients were more likely to receive chronic opioids than controls (6.9% vs. 3.8%). This risk remained following covariate adjustment (aHR 1.30; 95% CI 1.28, 1.32). Among gout patients, factors independently associated with an increased likelihood of chronic opioid exposure included more recent index year, younger age, female sex, non-Hispanic Black race/ethnicity, rural residence, being underweight or obese, former/current smoking, greater comorbidity, urate-lowering therapy receipt, and requirement of rheumatology consultation.</p><p><strong>Conclusion: </strong>Patients with gout are more likely to receive chronic opioids than non-gout counterparts, independent of other factors. This risk is greater in underrepresented gout populations, those with greater comorbidity, patients requiring rheumatology consultations and individuals prescribed urate-lowering treatments. Additional investigation is needed to elucidate whether deployment of optimal gout management minimizes chronic opioid exposure in patients with gout.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Longitudinal Association of Rheumatoid Arthritis Disease Activity with Phenotypic Frailty: Evidence for Secondary Frailty?","authors":"Hannah F Brubeck, Kylie E Riggles, Riley S Bass, Elizabeth R Wahl, George Mount, Dolores M Shoback, James S Andrews, Jose M Garcia, Ariela R Orkaby, Joshua F Baker, Patricia P Katz, Katherine D Wysham, Courtney N Loecker","doi":"10.1002/acr.25615","DOIUrl":"https://doi.org/10.1002/acr.25615","url":null,"abstract":"<p><strong>Introduction: </strong>The cross-sectional association between rheumatoid arthritis (RA) disease activity and frailty has been described, however the longitudinal relationship is less well understood. We evaluated the association between disease activity and frailty over time.</p><p><strong>Methods: </strong>We utilized a longitudinal RA cohort established at the VA Puget Sound Health Care System. RA disease activity (DAS28-CRP) and frailty (measured by the Fried Frailty Phenotype (FFP)) were evaluated at baseline and at 1-year. Frailty was categorized as robust, pre-frail or frail. Ordinal logistic regressions assessed the cross-sectional associations of DAS28-CRP and frailty at baseline and at 1-year. Paired t-tests and multivariable mixed ordinal logistic regressions assessed the longitudinal associations of DAS28-CRP and frailty. Models were adjusted for age, sex, disease duration, prednisone use, csDMARD and bDMARD use.</p><p><strong>Results: </strong>132 patients with RA aged 64.2±11.3 years were included, with 73% male (73%) and 69% White, 11% Black, and 12% reports multiple races. Mean baseline DAS28-CRP was 3.9±1.3 and 35 (27%) were robust, 77 (58%) prefrail, and 20 (15%) frail. DAS28-CRP (per 1 unit increase) was associated with higher FFP category at baseline (aOR: 1.98, p<0.0001). Disease activity increased in those whose frailty score worsened at 1 year (change score: 0.61±0.96, p=0.0121). Increased DAS28-CRP was independently associated with a higher frailty category over one year (aOR: 3.31, p<0.0001, N=65).</p><p><strong>Conclusion: </strong>Disease activity is independently associated with phenotypic frailty. Increased disease activity over time is associated with worsening frailty status. Future studies are needed to explore this longitudinal relationship and to determine if controlling disease activity can mitigate frailty.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lived and care experiences of chronic musculoskeletal shoulder pain in Australian adults: A qualitative study.","authors":"Sonia Ranelli, Joanne E Jordan, Ilana N Ackerman, Alison Thorpe, Jennifer G Persaud, Linda J Woodhouse, Jason Chua, Ben Horgan, Andrew M Briggs","doi":"10.1002/acr.25614","DOIUrl":"https://doi.org/10.1002/acr.25614","url":null,"abstract":"<p><strong>Objectives: </strong>Australian evidence on lived and care experiences of chronic musculoskeletal shoulder pain (CMSP), irrespective of disorder classification or disease, is limited. However, such evidence is important for person-centred care and informing local service pathways and care guidelines or standards. To address this gap, we explored i) lived experiences of adults with CMSP across domains of the International Classification of Function, Disability and Health (ICF) Framework, and ii) their care experiences, preferences and priorities for CMSP.</p><p><strong>Methods: </strong>A qualitative study, applying a phenomenological approach and purposive sampling was conducted with adults experiencing CMSP. Individual semi-structured interviews, informed by ICF domains, explored lived and care experiences/preferences of participants. Data were analysed using an inductive approach, by objective.</p><p><strong>Results: </strong>Twenty adults (50% women) with diverse CMSP conditions/diagnoses, clinical profiles and age (21-76 years) participated. Five lived experience themes were identified: 1) impact on body functioning; 2) impact on sleep, energy and drive; 3) impact on mental well-being and evolving sense of self; 4) coping with CMSP; and 5) social support and participation. Four care experience themes included: 1) care seeking choices; 2) interactions with healthcare professionals (HCPs); and 3) values and preferences for components of CMSP care.</p><p><strong>Conclusions: </strong>Adults with CMSP experience impacts across life stages in multiple domains of functioning (ICF categories) relating to personal and social dimensions. Clinical encounters, particularly interactions with HCPs, influence an individual's confidence and engagement in their care. Discussion, education and goal setting through shared decision-making are valued attributes of clinical encounters among people with CMSP.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treating lupus nephritis patients to lupus low disease activity reduces renal relapse and preserves long-term kidney function.","authors":"Chak Kwan Cheung, Desmond Yh Yap, K L Lee, Philip H Li, Iris Yk Tang, Chak Sing Lau, Shirley Cw Chan","doi":"10.1002/acr.25611","DOIUrl":"https://doi.org/10.1002/acr.25611","url":null,"abstract":"<p><strong>Objective: </strong>Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients with LN.</p><p><strong>Methods: </strong>Patients with LN during 2010-2020 in Queen Mary Hospital and Pamela Youde Nethersole Eastern Hospital were included in the discovery cohort and validation cohort, respectively. Complete renal response (CRR), partial renal response (PRR), LLDAS, and DORIS remission were assessed at 12 months. Regression analysis was performed to identify risk factors of LN relapse. Receiver operating characteristic (ROC) curves were used to evaluate target attainment and long-term kidney function.</p><p><strong>Results: </strong>A total of 245 LN patients (discovery cohort N=143, validation cohort N=102) were included. At 12 months, 57/143 (40%), 14/143 (10%), 70/143 (49%), 15/143 (10%) patients achieved CRR, PRR, LLDAS, and DORIS remission respectively. Attainment of both CRR/ PRR and LLDAS at 12 months was associated with best relapse-free survival (p<0.001). Multivariate analysis showed independent association of CRR/PRR and LLDAS with LN relapse risk reduction (CRR/PRR: HR=0.31, p = 0.007; LLDAS: HR=0.38, p = 0.029). LLDAS attainment predicts renal function preservation with satisfactory performance in both discovery and validation cohorts (AUC-ROC=0.71).</p><p><strong>Conclusion: </strong>LLDAS is an attainable target in LN comparable to CRR/PRR. Attainment of both targets is associated with additional benefit on relapse risk reduction. Early LLDAS attainment is associated with renal function preservation.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroxychloroquine Associated with Lower Glomerular Filtration Rate Decline in Lupus Nephritis.","authors":"Shivani Garg, Brad Rovin, Brad C Astor, Tripti Singh, Fauzia Hollnagel, Megan Kuik, Lexie Kolton, Callie Saric, S Sam Lim, Christie M Bartels","doi":"10.1002/acr.25616","DOIUrl":"10.1002/acr.25616","url":null,"abstract":"<p><strong>Background: </strong>Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long-term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our retrospective longitudinal inception LN cohort to examine the time-varying effects of HCQ on kidney function decline in LN.</p><p><strong>Methods: </strong>Retrospective data from an incident biopsy proven LN cohort. Creatinine values at LN diagnosis through the last follow-up were abstracted to estimate the glomerular filtration rate (eGFR). Using HCQ exposure as a time-dependent covariate, we examined associations between HCQ exposure and sustained eGFR decline ≥30% and ≥40%. We also calculated an annual eGFR slope decline by HCQ exposure using linear mixed effects analysis.</p><p><strong>Results: </strong>Among 209 patients, 33% & 23% experienced eGFR decline ≥30% and ≥40% over time. Time-varying HCQ exposure was associated with 60% and 62% lower risk of eGFR decline of ≥30% or ≥40%, after adjusting for propensity scores. An 77% lower risk of eGFR decline was noted in patients with CKD ≥3 with HCQ. HCQ exposure reduced the annual eGFR slope decline by 5.12 and 3.17 ml/min/1.73 m² within first 5 and 10 years of diagnosis.</p><p><strong>Conclusion: </strong>HCQ use was associated with early and long-term benefits on kidney function in LN, including those with CKD ≥3. Universal HCQ use should be encouraged in LN patients.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis.","authors":"Nilasha Ghosh, Pankti Reid, Jeffrey A Sparks, Kaitlin McCarter, Kyle Ge, Anne R Bass","doi":"10.1002/acr.25604","DOIUrl":"https://doi.org/10.1002/acr.25604","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to present effectiveness and tolerability of apremilast in a cohort of 21 patients with immune checkpoint inhibitor psoriatic arthritis (ICI-PsA) and/or immune checkpoint inhibitor psoriasis (ICI-PsO).</p><p><strong>Methods: </strong>This multicenter study combined data from patients treated with apremilast after experiencing ICI-PsO and/or ICI-PsA. Patients taking apremilast before ICI initiation and patients with preexisting autoimmune disease before ICI therapy were also included. Response to apremilast was determined as complete, partial, or none as determined by improvement in Common Terminology Criteria for Adverse Events grading after drug initiation.</p><p><strong>Results: </strong>There were 21 patients who used apremilast for either ICI-PsO and/or ICI-PsA, but only five of these patients had de novo ICI-PsO and/or ICI-PsA. Of these five patients, four had partial response or improvement in their immune-related adverse event with apremilast, although there were intolerances in three of these patients. Of the 21 total patients, 16 had a relevant preexisting autoimmune disease, indicating a likely flare of the underlying disease with ICI therapy. Flares occurred much sooner for patients with ICI-PsA (4 weeks) compared to patients with ICI-PsO only (39.7 weeks), although the majority of both groups had grade II severity. Among the 13 patients with preexisting disease and no exposure to apremilast before ICI therapy, all patients in the ICI-PsO-only group (100%) responded to apremilast with either a complete or partial response, whereas only 57% of patients in the ICI-PsA group had complete or partial response. Twenty-nine percent of patients in the entire cohort had to discontinue apremilast due to intolerability. Thirty-eight percent of the entire cohort had progression of cancer or death at last follow-up after being on apremilast.</p><p><strong>Conclusion: </strong>This study highlights the potential benefit of apremilast for the treatment of ICI-PsO, both de novo and PsO flare, with less of an apparent benefit for ICI-PsA. Thirty percent of patients in the whole group had to discontinue apremilast due to intolerance. Apremilast may be an attractive therapeutic option for either condition given that it is not immunosuppressive, but further prospective observational studies with larger patient numbers are needed.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Where, how, and how much? A multicenter cohort study of the relationship between lupus decision aid modality, place of administration, interruption and viewing completeness and patient-reported outcomes.","authors":"Jasvinder A Singh, Mark Beasley, Larry R Hearld","doi":"10.1002/acr.25603","DOIUrl":"https://doi.org/10.1002/acr.25603","url":null,"abstract":"<p><strong>Objective: </strong>We assessed whether shared decision-making (SDM), and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE), differs by PtDA setting, modality, and the viewing experience.</p><p><strong>Methods: </strong>Patients with SLE were invited to view a self-administered computerized SLE PtDA during regular clinic visits at 15 rheumatology clinics in an implementation trial. Patients completed a survey that included SDM measures including the decision-conflict (DCS), preparation for decision-making (PDM), and CollaboRATE scales; perceived patient acceptability, feasibility, and satisfaction. Patients viewed the SLE PtDA in two settings/places, in-clinic or at home (telemedicine visits), using one of three modalities, touchpad computer, smart phone, or a computer (desktop or laptop computer). We also assessed the effects of interruptions while viewing the PtDA and incomplete viewings.</p><p><strong>Results: </strong>We had a cohort of 813 (43% of 1,895 total) patients with SLE who completed the PtDA modality and setting questions, which were added mid-way after the COVID-19 pandemic started. In a multivariable-adjusted logistic regression analysis, the setting or modality of viewing the SLE PtDA were not associated with SDM or patient outcomes except the association of place of viewing with feasibility. We noted important significant association of interruption while viewing SLE PtDA with lower feasibility, acceptability and PDM and DCS scores; and incomplete viewing of the SLE PtDA with worse PDM and DCS scores.</p><p><strong>Conclusion: </strong>The SLE PtDA was effective regardless of setting and modality of delivery. Uninterrupted and complete viewing of the SLE PtDA is desirable for better SDM and higher acceptability.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering Race-Based Medicine in Pediatric Rheumatology: Challenges and Opportunities for Equitable Care.","authors":"Nayimisha Balmuri, Alisha Akinsete, Laura B Lewandowski, Mallet Reid, Jordan E Roberts, Jennifer M P Woo","doi":"10.1002/acr.25602","DOIUrl":"10.1002/acr.25602","url":null,"abstract":"<p><p>Despite growing evidence of their limitations, race-based practices in pediatric rheumatology-those that rely on race or ethnicity to influence diagnosis and treatment-continue to shape care, often reinforcing health disparities. The assumption that biologic or genetic differences exist between racial groups oversimplifies complex health issues and perpetuates health inequities. This article examines persistent race-based practices in pediatric rheumatology, particularly in the interpretation of laboratory results and clinical decision-making, and highlights their clinical limitations. For example, the use of race-adjusted formulas in evaluating estimated glomerular filtration rate, pulmonary function tests, and creatine kinase levels can lead to misdiagnoses and delayed interventions, particularly in Black and Asian populations. Additionally, race-based assumptions in diseases like Kawasaki disease and multisystem inflammatory syndrome in children can lead to incorrect conclusions about disease severity and treatment efficacy. This article advocates for a shift toward race-conscious practices that consider the role of social determinants of health and biases in clinical care. It also emphasizes the need for more inclusive research methodologies and diverse representation in clinical trials to enhance the generalizability of findings. By moving away from race-based practices and adopting equity-oriented frameworks, pediatric rheumatologists can better address the needs of marginalized populations and improve health outcomes. This shift is crucial in dismantling systemic disparities and advancing health equity in clinical and research settings.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of lung ultrasound interpretation criteria for ILD in systemic sclerosis and inflammatory myopathy: comment on the article by Fairchild et al.","authors":"Pablo Echevarría Díez-Canedo, Raquel Marín-Baselga, Yale Tung-Chen","doi":"10.1002/acr.25606","DOIUrl":"10.1002/acr.25606","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}